NCT02463669

Brief Summary

The purpose of this study is to determine if splenomegaly on point-of-care ultrasound (POCUS) is an accurate and user-friendly surrogate to the heterophile antibody test and Epstein-Barr Virus (EBV) serologies to diagnose acute mononucleosis infection in patients presenting with sore throat to the Emergency Department (ED).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Apr 2016

Longer than P75 for all trials

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 31, 2015

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 4, 2015

Completed
10 months until next milestone

Study Start

First participant enrolled

April 1, 2016

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 4, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 4, 2020

Completed
Last Updated

October 6, 2020

Status Verified

October 1, 2020

Enrollment Period

4.5 years

First QC Date

May 31, 2015

Last Update Submit

October 4, 2020

Conditions

Keywords

Point-of-care ultrasound

Outcome Measures

Primary Outcomes (1)

  • Presence of splenomegaly (maximal splenic cranio-caudal length) on point-of-care ultrasound

    Splenomegaly is defined as a splenic length of \> 11.5 centimetres (cm) for 10-12 year-old patients, \> 12 cm for 12-15 year-old patients, \> 12 cm for 15-35 year-old female patients, and \> 13 cm for 15-35 year-old male patients.

    12 months

Interventions

Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.

Eligibility Criteria

Age10 Years - 35 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Convenience sample of patients between July 2016 and October 2017. Inclusion criteria are patients aged between 10 and 35 year-old presenting to the ED with suspected acute infectious mononucleosis.

You may qualify if:

  • Patients aged between 10 and 35 year-old presenting to the ED with suspected acute infectious mononucleosis

You may not qualify if:

  • Chronic infectious disorders (eg. tuberculosis, malaria, HIV, syphilis)
  • Inflammatory disorders (eg. sarcoidosis, amyloidosis, systemic lupus erythematosus, Felty syndrome)
  • Proliferative disorders (eg. lymphoma, leukemia, essential thrombocytopenia, polycythemia vera)
  • Congestive disorders (eg: cirrhosis, portal hypertension, right heart failure, congenital heart disease)
  • Chronic haemolytic anemia (eg. sickle cell, thalassemia, hereditary spherocytosis)
  • Storage diseases (eg. Gaucher, Niemann-Pick)
  • Splenectomy
  • Inability to give informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU Sainte-Justine

Montreal, Quebec, H3T 1C4, Canada

Location

Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada

Location

MeSH Terms

Conditions

Infectious MononucleosisSplenomegaly

Condition Hierarchy (Ancestors)

Epstein-Barr Virus InfectionsHerpesviridae InfectionsDNA Virus InfectionsVirus DiseasesInfectionsLeukocyte DisordersHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesHypertrophyPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Laurie Robichaud, MD

Study Record Dates

First Submitted

May 31, 2015

First Posted

June 4, 2015

Study Start

April 1, 2016

Primary Completion

October 4, 2020

Study Completion

October 4, 2020

Last Updated

October 6, 2020

Record last verified: 2020-10

Locations